XOMA Royalty (XOMA) Net Cash Flow (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Net Cash Flow came in at $5.0 million in Q1 2026, up 144.19% year-on-year from $2.1 million in Q1 2025, and up 59.42% quarter-over-quarter from $3.2 million in Q4 2025.
XOMA Royalty (XOMA) Net Cash Flow (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Net Cash Flow across 17 years of filings, most recently posting $5.0 million for Q1 2026.
- Net Cash Flow for Q1 2026 came in at $5.0 million, up 144.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $43.7 million (up 192.28% YoY), and the FY2025 annual result was $27.3 million, up 151.37% from the prior year.
- Net Cash Flow came in at $5.0 million for Q1 2026 at XOMA Royalty, up from $3.2 million in the prior quarter.
- In the past five years, Net Cash Flow ranged from a high of $126.1 million in Q4 2023 to a low of -$40.4 million in Q4 2024.
- The 5-year median for Net Cash Flow is -$5.5 million (2022), against an average of $2.6 million.
- Peak annual rise in Net Cash Flow reached 1777.45% in 2025, while the deepest fall reached 320.0% in 2025.
- XOMA Royalty's Net Cash Flow stood at -$20.5 million in 2022, then soared by 716.25% to $126.1 million in 2023, then plunged by 132.04% to -$40.4 million in 2024, then jumped by 107.81% to $3.2 million in 2025, then soared by 59.42% to $5.0 million in 2026.
- The last three Net Cash Flow figures came in at $5.0 million (Q1 2026), $3.2 million (Q4 2025), and $52.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 2.44 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 625.70 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -2.44 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 457.40 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 664,983.53 |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | 5.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.03 Mn |
| Mar 31, 2026 | 5.03 Mn |
| Dec 31, 2025 | 3.16 Mn |
| Dec 31, 2025 | 3.16 Mn |
| Sep 30, 2025 | 52.07 Mn |
| Sep 30, 2025 | 52.07 Mn |
| Jun 30, 2025 | -16.54 Mn |
| Jun 30, 2025 | -16.54 Mn |
| Mar 31, 2025 | -11.39 Mn |
| Mar 31, 2025 | -11.39 Mn |
| Dec 31, 2024 | -40.40 Mn |
| Dec 31, 2024 | -40.40 Mn |
| Sep 30, 2024 | -3.10 Mn |
| Sep 30, 2024 | -3.10 Mn |
| Jun 30, 2024 | 7.52 Mn |
| Jun 30, 2024 | 7.52 Mn |
| Mar 31, 2024 | -17.15 Mn |
| Mar 31, 2024 | -17.15 Mn |
| Dec 31, 2023 | 126.08 Mn |
| Dec 31, 2023 | 126.08 Mn |